Objectives: Mild therapeutic hypothermia after out-of-hospital cardiac arrest is usually achieved either by surface cooling or by core cooling via the patient's bloodstream. We compared modern core (Coolgard) and surface (Arctic Sun) cooling devices with a zero hypothesis of equal cooling, complications, and neurologic outcomes.
I nduction of mild therapeutic hypothermia (MTH) to reduce secondary reperfusion brain injury in comatose patients is one of few proven in-hospital treatment strategies for out-of-hospital cardiac arrest (OHCA) (1, 2) . Although MTH can be induced and maintained with basic means such as ice packs, cold air blankets, or infusion of cold fluids (2, 3) , numerous advanced systems have been developed with the intention of achieving faster induction and more reliable temperature maintenance (4, 5) . These systems rely on two distinct approaches to whole-body cooling, either surface cooling of the patients' skin or core cooling with an endovascular catheter. The clinical effect of choosing either surface cooling or core cooling is uncertain, because most studies have compared modern cooling devices to no or only basic cooling, such as cold air blankets or ice packs (4) .
Our hospital uses either an advanced endovascular core cooling device (Coolgard; ZOLL Medical Corporation, Chelmsford, MA ) or an advanced surface cooling device (Arctic Sun; Medivance, Louisville, CO) as part of a previously described standard operating procedure for all OHCA patients (6) . These devices are fairly comparable in terms of cooling effectiveness and automatic temperature feedback control (4) . Based on prospectively collected data from all comatose OHCA patients treated and nonrandomized at our institution with either of these two devices, we compared core and surface cooling with a zero-effect hypothesis of equal cooling effectiveness and patient outcomes. To our knowledge, this is the first study comparing these two frequently used devices related to outcome, complications, and other physiologic and metabolic effects.
MATERIALS AND METHODS
The study and the scientific use of the hospital postresuscitation registry data were approved by the Norwegian Board of Health and the Regional Committee for Medical Research Ethics of Eastern and Southern Norway.
Organization. Oslo University Hospital is Norway's largest health institution, with 20,000 employees across three individual hospitals. The largest, Oslo University Hospital-Ulleval, is the local hospital for 200,000 and the regional hospital and trauma center for 1.4 million people, admitting approximately 45,000 patients per year. Ulleval has 40 intensive care unit (ICU) beds across seven ICUs, but OHCA patients are treated mainly in the Medical and Cardiac ICUs. The hospital is a regional 24-hr percutaneous coronary intervention center.
Patients. All adult (age older than 18 yrs) OHCA patients treated at Ulleval have been consecutively recorded in the postresuscitation registry since 2003. Patients are identified from emergency department and ICU records and double-checked via the hospital computerized patient diagnosis registry. All comatose OHCA patients treated with either Coolgard or Arctic Sun between September 2003 and January 2009 were included in this study. Patients transferred to Ulleval as secondary percutaneous coronary intervention hospital were excluded from the study.
Standard Operating Procedure. All OHCA patients brought to Ulleval are treated in accordance with a standard operating procedure that includes MTH for all comatose patients, irrespective of initial electrocardiogram rhythm or presumed cause of arrest (6) . Relative contraindications are trauma or primary coagulopathy, in which a risk vs. benefit evaluation is required on a patient-by-patient basis. Absolute contraindication is a situation in which active intensive care is judged inappropriate on the basis of end-stage malignancy, a standing do-not-attempt-resuscitation order, or minute chances of meaningful survival (not witnessed arrests with asystole, lengthy resuscitation, or advanced age). Treatment withdrawal is considered in patients who remain comatose 72 hrs after rewarming based on similar individual patient factors as well as prognostication from neurologic examination, electroencephalography, and computed tomography scans.
When MTH is indicated, cooling is initiated immediately in the emergency department on hospital arrival with ice packs around the groin, armpits, and neck and infusion of up to 3 L of refrigerated NaCl 0.9% (30 mL/kg, 4°C). All patients are deeply sedated with either midazolam or propofol in combination with fentanyl to Motor Activity Assessment Scale (7) zero, and shivering is primarily treated by increasing anesthetics. Muscle relaxants are used only as intermittent bolus injections when sedation alone fails to control shivering, or in cases in which difficult respirator treatment requires it. The standard op-erating procedure makes no distinction between the two available devices for maintaining MTH (Arctic Sun and Coolgard) as the primary choice and advises the use of improvised maintenance with ice packs and soaked towels only when neither device is available.
The Coolgard device circulates water in a closed system through an endovascular catheter with water temperature controlled with "closed-loop" temperature feedback from the patient (8) . Arctic Sun functions in an analogous manner with the exception that the water is circulated through a system of adhesive plates cooling the patient's skin (9) . Both systems are commercially available and widely used in clinical practice (5) .
Objectives. We compared observed differences between patients treated with surface vs. core cooling in cooling rates, complications, and adverse events during ICU stay, need of adjuvant ICU therapies, and good neurologic function at hospital discharge and follow-up. Good neurologic function is defined as cerebral performance category 1 (normal without disability) or 2 (moderate neurologic disability) (10) .
Prehospital data were extracted from paramedic charts, call-center records, and electronic defibrillator data. Biochemical variables (glucose and electrolyte levels) were collected from the electronic hospital laboratory records, whereas timeframes, medication, and therapies were collected from ICU charts. Treatment in the ICU during MTH followed the comprehensive standard operating procedure (6) available for the nurses and physicians. ICU nurses documented shivering if it persisted despite best effort to abolish symptoms with sedation (Motor Activity Assessment Scale zero) or if muscle paralysis was required. Electroencephalography was recorded when seizures were suspected and thereafter were evaluated by a consultant neurologist. Arrhythmias were registered only when requiring treatment or intervention. Pneumonia was diagnosed and antibiotics were administered based on clinical signs, laboratory findings, and chest radiographs not awaiting bacterial cultures. Prophylactic antibiotics were not used. All diagnosis and complications recorded are those charted by treating ICU physicians, cardiologists, or consultant neurologists based on clinical evaluations and available medical tests. The patients' primary physicians and local hospitals responsible for the long-term care of the patients were contacted after 6 to 12 months for information on overall neurologic function and survival.
Statistical Analysis. Statistical analysis was performed using SPSS version 16 (SPSS, Chicago, IL). Continuous variables are presented as medians with interquartile ranges and analyzed using the Mann-Whitney U test, whereas proportions are presented as fractions of total (missing data deducted) and analyzed using the Pearson chi-square test or Fisher's exact test as appropriate. p Ͻ .05 was regarded as statistically significant.
A multiple logistic regression model was used to analyze factors that affect survival to discharge with good neurologic function. Tabulated prognostic factors, complications, adverse events, and ICU therapy data were entered in a forward variable selection procedure. The MTH method was removed by the forward method and re-entered into the final model to calculate its adjusted odds ratio for neurologic successful survival.
RESULTS
In the 5.5-yr study period, 353 patients were admitted to Ulleval after OHCA, of whom 92 were treated with Arctic Sun and 75 were treated with Coolgard, for a total of 167 included patients (Figs. 1 and 2). Baseline characteristics for the patients and cardiac arrest episodes were not significantly different in the two treatment groups ( Table 1 ). Both devices were deployed with a comparable time from cardiac event, initial temperature, and frequency of initial adjuvant cooling with ice packs and cold fluids ( Table 2 ). There were no significant differences in survival to final hospital discharge with good neurologic function (cerebral performance category 1 or 2) between the two treatment groups. Median (interquartile range) time to follow-up after discharge was 11 (7, 13) months, and there were no significant difference either in survival or cerebral performance category at follow-up ( Table 2 , Fig. 1 ).
We did not find any device-specific patient injuries in the study period, skin injuries with surface cooling, or catheterassociated thrombosis or embolism. Lengths of ICU stay, durations of respirator dependency, rates of MTH discontinuation, and postcooling fever were not significantly different in the two groups ( Table 2) . Infection rates and antibiotic treatment, arrhythmias, level of hemodynamic support, transfusion rates, presence of seizures or shivering, use of paralytic agents, and need for dialysis were also comparable ( Table 3) .
Episodes of sustained hyperglycemia (serum glucose Ͼ8 mmol/L) of Ͼ4 consecutive hours were significantly more frequent among surface-cooled patients ( Table 3) . Insulin use and the rate of hypoglycemia were not significantly different in the two groups (Table 3 ). There was a significantly higher rate of low serum magnesium (serum magnesium Ͻ0.7 mmol) among core-cooled patients ( Table 3 ). Figure 3 illustrates all complication rates split between the two treatment groups. Cumulative number of patients recruited with surface (continuous line) and core (dashed line) cooling by date of arrest. The core cooling method was introduced into our clinical practice earlier than the surface cooling method, resulting in the former dominating the early period and the latter dominating the late period of the study. 
DISCUSSION
In this observational study of contrasting core and surface cooling in comatose survivors of OHCA undergoing MTH, complications were rare and comparable between the devices. Sustained hyperglycemia was more common in patients undergoing surface cooling, and hypomagnesemia was more often seen in patients with core cooling. Survival with good neurologic function was 41% in the overall cohort, with no survival difference noted between the groups.
Hyperglycemia is a common adverse event among critically ill patients (11, 12) and has been associated with worse outcome after cardiac arrest in previous studies (13) (14) (15) . However, the patients receiving MTH in the study by Bernard et al (2) had improved outcome despite significantly higher blood glucose levels during the first 12 hrs compared to normothermic patients. In the present study, most hyperglycemic episodes were attributable to failed control of initial high glucose levels, and high glucose levels on hospital admission might be secondary to more difficult and prolonged resuscitation (16) .
An interesting finding was a higher rate of hyperglycemia among surfacecooled than among core-cooled patients. This previously has been described in pigs comparing aortic flush to surface cooling (17) and in infants undergoing cardiac surgery with surface and core cooling (18) . Increased insulin requirements during hypothermia is understood to be attributable to a combination of decreased insulin secretion and a moderately increased insulin resistance (19) , and the higher rate of hyperglycemia among surface-cooled patients might be linked to either or both of these mechanisms.
Among the patients receiving insulin in our study, satisfactory blood sugar control was much less frequently achieved among the surface-cooled patients. This leads us to speculate that the higher rate of hyperglycemia with surface cooling is attributable to increased peripheral insulin resistance, although this question requires further studies of serum insulin levels and peripheral glucose uptake during MTH.
The high rate of low serum magnesium among core-cooled patients in other studies has been associated with adverse outcome in critically ill and acute coronary care patients (20, 21) . It is known that electrolytes shifts from extracellular to intracellular compartments during cooling (22) , but why this shift appears greater among core-cooled patients than surface-cooled patients with comparable cooling rates is puzzling. Electrolyte depletion also might be attributable to increase urinary excretion caused by hypothermia-induced polyuria (22) . However, we found no difference in renal failure rates, with few patients requiring dialysis in both treatment groups compared to other published data (23, 24) .
Skin temperature is known to influence thermoregulatory control (25) , and it previously has been speculated that core cooling could result in less shivering (26) . However, this could not be confirmed in the present study, because there was no difference in the rate of shivering in surface-cooled or corecooled patients. This might be attributable to the fact that we used deep sedation in all patients, regardless of cooling method, aiming to sufficiently lower the threshold for shivering. Interestingly, patients with a difficult-to-extinguish shivering response had higher odds of neurologic intact survival. Shivering slows the rate of cooling and therefore could adversely affect outcome (27) , but as a normal physiologic response it also indicates preservation of neurologic function and might be an important confounding factor explaining the lack of association between cooling rates and outcome in nonparalyzed patients (28) .
Two comprehensive reviews in 2009 (4, 5) evaluated the available literature regarding practical considerations and cooling methods for inducing and maintaining MTH, identifying only a few studies comparing currently available surface and core cooling devices to each other. Hoedemaekers et al CPC, cerebral performance category. a Two-sided p calculated with Mann-Whitney U test or 2 test as appropriate; b there are missing survival to final hospital discharge data for two patients(foreign citizens) who were transferred to hospitals outside Norway; c there are missing survival and CPC data for four patients (foreign citizens) who had returned abroad before follow-up; d time to follow-up after discharge was 11 (7, 13) months. Ratios are presented as absolute numbers (percentage) and continual variables are presented as median (interquartile range).
(29) compared induction speed and temperature maintenance stability of five different cooling methods in neurointensive care patients, conventional cooling by cold fluid/ice packs, a core cooling device, one air-circulating surface cooling device, and two watercirculating surface cooling devices. The core cooling device and two watercirculating surface cooling devices had similar advantages in induction speed compared to conventional or aircirculating cooling, with all three having cooling rates Ͼ1°C per hour. In contrast, our patients were cooled in the acute setting after OHCA, while being received by the emergency department, while being moved to angiography laboratories (approximately twothirds of all patients), and subsequently while being admitted to an ICU. Because cooling is initiated and sustained with ice packs and cold fluids only before ICU admission, and because cooling catheters are often placed during treatment in the angiography laboratories or emergency department, there is no substantial delay in deployment of either device after arrival in the ICU. In this setting, both cooling strategies resulted in a similar time of approximately 4.5 hrs from time of arrest or approximately 3 hrs from initiation of cooling to reach 34°C. Our cooling rates were not comparable to those demonstrated by Hoedemaekers et al (29) , but the clinically relevant time from arrest to achieved MTH is similar to that of other recently published OH-CAs (8, 27, 30, 31) , It is noteworthy that this timeframe is not different from what was achieved in a recent Swedish OHCA study (3) using only basic cooling with ice packs and cold fluid resuscitation, considering the cost savings with simpler cooling methods compared to the two commercial devices.
This study has the limitation of comparing two nonrandomized treatment methods based on observational registry data. However, data acquisition for our registry is thorough and the chance of lost cases in the study period is minimal. The lack of randomization and blinding might have caused bias and, in many cases, hospital logistics left the attending doctor with only one device being available. Further, the core cooling method was introduced into our clinical practice earlier than the surface cooling method, resulting in the former dominating the early study period and the latter dominat- ing the late study period (Fig. 2) . This introduces bias similar to that of beforeand-after studies, in which subtle changes in clinical practice might affect the comparison between the two methods, although the postresuscitation treatment protocol remained unchanged throughout the study period. It is important to emphasize that observational studies frequently do not overestimate the magnitude of treatment effects (32) . Last, this study revealed a nonsignificant absolute difference in neurologic intact survival of 7%, with only a power of 16.5%, requiring 672 patients in each group to achieve a power of 80% to uncover an unadjusted difference of this magnitude. However, the adjusted odds ratio for survival of 0.89 had a large 95% confidence interval of 0.36 to 2.20, with p ϭ .800.
CONCLUSIONS
There was no significant difference in outcome or in time to achieve MTH with surface vs. core cooling of OHCA patients following the same established postresuscitation treatment protocol. There was a higher rate of hyperglycemic episodes and a lower rate of hypomagnesaemia with surface cooling. Because hyperglycemia and hypomagnesaemia have been associated with worse outcome in critically ill patients, a larger randomized study comparing these two different cooling methods is warranted. Factors initially entered to the forward procedure: hypothermia method, gender, coronary disease, heart failure, hypertension, diabetes, pulmonary disease, hepatic disease, malignant disease, drug/ alcohol abuse, witnessed arrest, bystander basic life support, time to return of spontaneous circulation, adjuvant cooling, bleeding requiring transfusion, infection, antibiotics, fever, arrhythmias, pacemaker, vasoactive medication, intra-aortic balloon pump, anticonvulsants, muscle relaxants, hyperglycemia, hypoglycemia, potassium, and dialysis.
a Myoclonus or epileptic seizures diagnosed by consultant neurologist and electroencephalogram findings; b insulin administered during the first 72 hrs after cardiac arrest; c shivering cold response during therapeutic hypothermia; d pre-existing neurologic disease with function impairment(stroke sequels or epilepsy); e therapeutic hypothermia method was not significant and forced into the regression analysis with no effect on the model.
